Company intelligence / Profile preview

Critical Therapeutics, Inc.

Lexington, Massachusetts, United Statessec.gov ↗

Ownership: Private
Development stage: NDA

Overview

Critical Therapeutics developed and commercialized innovative products for respiratory, inflammatory, and critical care diseases. Its lead product was ZYFLO CR™ (zileuton extended-release tablets) and ZYFLO® (zileuton tablets), both FDA-approved for asthma. The company also pursued therapies targeting the body’s inflammatory response. It merged with Cornerstone BioPharma in late 2008 to form Cornerstone Therapeutics Inc., which itself was later acquired by Chiesi USA in 2014[1][5][6].

Therapeutic areas: OtherPulmonologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

zileuton

Commercial

Indications: Asthma

2 more assets in the full pipeline.

Request access →

Partnerships

MedImmune – exclusive license/collaboration agreement for novel drug discovery/development as of July 2003DEY L.P. – co-promotion arrangement for Perforomist™ inhalation solution

Beyond the preview

Go deeper on Critical Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Critical Therapeutics, Inc..

Explore the full profile